---
document_datetime: 2025-12-19 08:23:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/altuvoct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: altuvoct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6921387
conversion_datetime: 2026-01-03 12:57:41.254111
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ALTUVOCT

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000274459 | - -     | 16/10/2025                          | 12/12/2025                                  | SmPC and PL                      | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | In view of available data on hypersensitivity reactions from spontaneous reports, including in some cases a close temporal relationship, a positive de-challenge and/or re-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between efanesoctocog alfa and hypersensitivity reactions including anaphylaxys is at least a reasonable possibility. The PRAC concluded that the product information of products containing efanesoctocog alfa should be amended accordingly.   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000269780 | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted                                                                                                                                                                                                                                                                                                                                             | 24/07/2025 | N/A |
| Variation type IB / EMA/VR/0000269881 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                                                   | 30/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000261918   | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted B.IV.1.a Addition or replacement of a device which is not an integrated part of the primary packaging - B.IV.1.a.1 Device with CE marking - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging   | 08/04/2025   | N/A   |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000255925      | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/03/2025   | N/A   |